TRENDING :  Market Movers  |  Top 50   SPY (0.23%)    TSLA (-2.49%)    CANF (1.36%)    BYND (-2.96%)    BTCUSD (%)    ONCS (-3.12%)    AMZN (0.43%)    TVIX (-4.25%)    VXX (-2.07%)    ROKU (6.45%)    ACAD (2.45%)    OIH (-1.43%)    MCHP (-1.44%)    MAXR (-13.79%)    IRBT (0.03%)    IP (-0.24%)    INTC (0.09%)    GDX (0.64%)    FTNT (0.33%)    ECOR (-4.53%)    DNR (3.23%)    DIS (0.05%)    DFRG (2.06%)    CMG (-0.69%)    BIOC (9.74%)

 CRSP - CRISPR Therapeutics AG

$37.00 [0.19][0.52%]

Next Earnings



Trade Idea »


No recommendations found.

This list is limited to recommendations made in last 7 days only. Subscribe to a service to see all their recommendations.



5 Growthy Biotech Stocks to Buy Despite the Scrutiny

InvestorPlace Stock Market News Stock Advice amp Trading Tips One would think that the biotechnology sector is immune from trade tensions but that is not the case Biotech stocks are very much prone to selloffs during heightened global insecurity In general U S China trade tensions

Why CRISPR Therapeutics Gained 13.4% in April

What happened Shares of the gene editing upstart CRISPR Therapeutics AG NASDAQ CRSP rose by a market beating 13 4 in April according to data from S amp P Global Market Intelligence The biotech s stock perked up after the company announced that the Food and

CRSP Crosses Below Key Moving Average Level

In trading on Tuesday shares of CRISPR Therapeutics AG Symbol CRSP crossed below their 200 day moving average of 39 08 changing hands as low as 38 78 per share CRISPR Therapeutics AG shares are currently trading off about 7 on the day The chart below shows the one year performance of

Vertex Pharmaceuticals Looks to Jump From 18,000 Patients to 68,000

Vertex Pharmaceuticals NASDAQ VRTX continues its march to higher revenue with the launch of its newest double combination cystic fibrosis drug Symdeko as the biotech waits for its next major growth inflection point from a yet to be named triple combination Vertex

Vertex (VRTX) Q1 Earnings and Revenues Surpass Estimates

Vertex Pharmaceuticals Incorporated 160 VRTX delivered first quarter 2019 earnings per share of 1 14 beating the Zacks Consensus Estimate of 98 cents Moreover the figure came ahead of the year ago earnings of 76 cents Strong cystic fibrosis CF product revenues led to higher profits

Better Buy: Editas Medicine vs. CRISPR Therapeutics

Wouldn t it be great to be able to modify DNA sequences to fix genetic mutations that cause serious diseases Two companies attempting to do just that are Editas Medicine NASDAQ EDIT and CRISPR Therapeutics NASDAQ CRSP Both biotechs focus on the use of CRISPR gene